Results

Total Results: 2,034 records

Showing results for "time".

161. Reduction in Medication Use after Bariatric Surgery (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/bariatric-surgery_research.pdf
     June 01, 2010 - We compared the mean number of medications at the time of surgery and in the subsequent year. … tabulated the number of unique therapeutic classes of drug that the patient had ―on hand‖ at the time … in the patient having sufficient drug ―on hand‖ to overlap with a seven day window surrounding the time … We tabulated the mean number of medications at each time period for the figures. … Over the same time period, antihistamine use decreased by 15%.

162. Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: Final Update of a Rapid, Living Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-3-immunity-after-COVID-19.pdf
     December 31, 2022 - age, gender, race/ethnicity, and comorbidities), COVID- 19 disease severity, presence of symptoms, time … may remain detectable for at least 120 days according to the study with the longest followup at the time … From 9 to 20 months of followup, during which time Delta was prevalent, protection against infection … and it is likely that, if antibodies are present, the individual will have some protection at the time … Was the follow up time reported and sufficient to be long enough for outcomes to occur? 9.

163. Title (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mental-illness-adults-prisons_research-protocol.pdf
     September 13, 2012 - Was the treatment applied consistently across study subjects and over time? … Did ≥85% of enrolled patients provide data at the time point of interest? 12. … Depending on time constraints of the review, we may grade additional outcomes as well. … Time to prison return for offenders with serious mental illness released from prison. … Policy brief: critical time intervention for prison and jail reentry.

164. Covariate Selection for Observational Comparative Effectiveness Research
     effectivehealthcare.ahrq.gov/sites/default/files/covariate-selection-chapter-7.pptx
     January 01, 2013 - 0) and Y1 is the outcome after followup (time 1). … Risk Factors We now let C0 be one or more baseline covariates measured at time 0. … Confounding by indication and channeling over time: the risks of beta 2-agonists. … Both the “as treated” and “per protocol’’ analyses can be used to evaluate time-varying treatment. … In a nonexperimental setting, time-varying treatments are expected to have time-varying confounders.

165. Rapid Evidence Product_Assisted Home Dialysis in the United States: New Interest in an Old Idea (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/home-dialysis-ESKD-rapid-research.pdf
     April 01, 2025 - there was fraud going on in Florida and CMS had to put an end to all assisted home dialysis at the time … The pilot program trained nonmedical personnel who could manage home HD for brief periods of time (3 … There was no comparison “All the time that someone spends giving care, that is time away from them … Long-term or respite [12-month pilot; For respite care: median time to return to self-care 29 … ) • Education/training for home HD/PD Comparator Any, none Outcomes • Length of time on assisted

166. EHC Protocol: Addressing Social Isolation To Improve Health of Older Adults: A Rapid Evidence Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/making-healthcare-safer-IV.pdf
     August 04, 2023 - What resources (e.g., cost, staff, time) are required for implementation of infection surveillance … Targeted Multidrug-resistant Organisms (MDROs).6 Owing to these organisms’ increasing prevalence over time … Owing to the limited time and funding allocated to this update on infection surveillance PSP, along … streamline traditional systematic review processes and deliver an evidence product in the allotted time … What resources (e.g., cost, staff, time) are required for implementation of infection surveillance PSPs

167. Methods Research Report Improving Access To And Usability of Systematic Review Data for Health Systems Guideline Development (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-health-systems-guidelines-development.pdf
     February 01, 2019 - MAGICapp required less time and skill to mock up, as the data were entered manually into the Web-based … platform, while Tableau required more time and a staff member with knowledge of informatics such as … As we were inputting data from a static report into the platform, the bulk of the time in developing … During this time, Dr. … Thank you for your time and participation. b. If no, thank you for your time and participation.

168. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/alternative-payment-models-protocol.pdf
     December 16, 2024 - where a single payment is made for all services related to a treatment or condition over a specific time … Assessing the sustainability of outcomes and cost savings over time is also essential to determine the … Finally, we aim to evaluate state- level differences (e.g., expansion state at the time of the evaluation … (savings)) OR (title: (analysis)) OR (title: (evaluation)) OR (title: (evaluations)) OR (title: ("time … OR (abstract: (analysis)) OR (abstract: (evaluation)) OR (abstract: (evaluations)) OR (abstract: ("time

169. App-E-Surv-Report-3-Acute-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-3-acute-pain.xlsx
     May 29, 2025 - Breastfeeding Pain Duration Overall Baseline Pain Standardized Scale 0 to 10 Treatment Duration Assessment Time … Total treatment time 8 to 9 minutes, and standard treatment B: Standard treatment: Advice about activity … to 2.5) vs. 1.7 (1.1 to 2.6) day 28; 1.5 (1.0 to 2.1) vs. 2.05 (1.5 to 2.5) at 1 year; p>0.05 at all time … day 28, 3 (2 to 4) vs. 4 (3 to 5) day 84, 2.5 (1.5 to 3.5) vs. 4 (3 to 5) at 1 year; p>0.05 at all time … 2.01, 95% CI 0.86 to 4.72 day 1; OR 0.73, 95% CI 0.22 to 2.37 day 14 EQ-5D-3L: No differences at any time

170. App-E-Surv-Report-2-Acute-Pain (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surv-report-2-acute-pain.xlsx
     May 29, 2025 - Breastfeeding Pain Duration Overall Baseline Pain Standardized Scale 0 to 10 Treatment Duration Assessment Time … Total treatment time 8 to 9 minutes, and standard treatment B: Standard treatment: Advice about activity … to 2.5) vs. 1.7 (1.1 to 2.6) day 28; 1.5 (1.0 to 2.1) vs. 2.05 (1.5 to 2.5) at 1 year; p>0.05 at all time … day 28, 3 (2 to 4) vs. 4 (3 to 5) day 84, 2.5 (1.5 to 3.5) vs. 4 (3 to 5) at 1 year; p>0.05 at all time … 2.01, 95% CI 0.86 to 4.72 day 1; OR 0.73, 95% CI 0.22 to 2.37 day 14 EQ-5D-3L: No differences at any time

171. Tonsillectomy for Obstructive Sleep-Disordered Breathing or Recurrent Throat Infection in Children (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/tonsillectomy_executive.pdf
     January 01, 2017 - In two RCTs comparing diclofenac with or without other analgesics to lidocaine or placebo, time to … These benefits did not persist over time, however, and data on the longer- term outcomes are limited … Long-term effects are limited in the literature base, particularly regarding outcomes that include … These benefits did not persist over time, and data on longer-term results are lacking. … Does tonsillectomy lead to improved outcomes over and above the effect of time?

172. Registry of Patient Registries (RoPR) Policies and Procedures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/registry-of-patient-registries_research-2012-2_1.pdf
     January 01, 2012 - to completion for time-sensitive registries … Stakeholders also noted that, as more patient registries are listed over time, the RoPR will likely … Advisors should serve on the board for a defined period (e.g., 1 to 2 years), during which time they … Over time, it is anticipated that more of these data elements may be required as the number of RoPR … In addition, the RoPR will track changes to registry listings over time.

173. Insomnia Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_executive.pdf
     December 01, 2015 - sleep efficiency (total sleep time/total time in bed). … in bed to sleep time, gradually increasing time in bed as sleep efficiency improves. … after sleep onset, total sleep time, sleep efficiency [total sleep time/total time in bed], and sleep … after sleep onset and increases in total sleep time. … and wake time after sleep onset in the general adult population.

174. S3 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s3.pdf
     October 01, 2007 - this arena and his approach to the practice of medicine were extraordinary and revolutionary for the time … unique career as Vice President of Epidemiology at Merck Research Lab- oratories, Harry joined UNC full time … We miss him, and recall him fondly each time the Tar Heels take to the hard- wood, and we know that his … Exposure-time-varying hazard function ratios in case-control studies of drug effects.

175. Facilitating the Implementation of EPC Reports_Methods Research Report (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-facilitating-implementation-pilot.pdf
     October 01, 2019 - stakeholders is essential to determine what information is important to health systems at a given time … to create a tool or a product after the publication of the report will likely be needed most of the time … start with a needs assessment and development of a charter; which is almost always unknown at the time … Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: immediate and long-term … effects using a blind randomized controlled trial.

176. Introduction (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine-1_research.pdf
     February 01, 2009 - December 31 each year (point prevalence) and evaluated age-specific changes in medication use over time … The utilization of other synthetic DMARDs decreased over time (p<0.001 for each) (Figure 2A). … Overall, the proportion of patients without study medications on the index date decreased over time. … DMARD utilization increased over time indicating that more RA patients who used DMARDs, remained on … In contrast to previous estimates of DMARD utilization that were based on prevalence of use at any time

177. Protocol for Quantitative Assessment of Benefit and Harm analysis of Aspirin for primary prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-balancing-harms-benefits_research.pdf
     February 01, 2014 - The baseline risk of these outcomes without aspirin for a time horizon of 10 years; and c. … did not change over the time horizon of 10 years. … risk over time Incidence rate of all outcomes without treatment did not change over time. … Incidence rate of all outcomes without treatment did not change over time. … and harm outcomes did not change over time.

178. Module II: Stakeholders and Stakeholder Engagement (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/module-ii-stakeholders-and-stakeholder-engagement.pdf
     June 01, 2011 - to recognize their expertise and provide an overview of the research process and expectations for time … Investigators may need to allow for and address issues related to the time providers’ participation … Strategies for Engaging Policymakers § Explain value and benefit § Recognize expertise § Address time … Policymakers often hope for, or expect, rapid turnaround, just in time information, or “good enough” … Lost in Knowledge Translation: Time for a Map?

179. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer18-heart-disease-ace-inhibitor-arb-executive.pdf
     October 01, 2009 - Thus it seems plausible that this period of time should be given following a revascularization procedure … However, no studies have prospectively investigated the optimal time to begin therapy, and more concrete … As such, current evidence does not support the use of combination therapy at this time. … Symptom reporting Moderate • ACE inhibitor (zofenopril) therapy increases the time to onset of ischemic … in subjects with different presence and pattern of angina symptoms cannot be determined at this time

180. Appendix K Rapid Evidence Review Treatments for Clostridium difficile Colitis (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/clinical-pathway-methods-report-appendix-k.pdf
     February 01, 2018 - • There are insufficient data at this time to recommend extending the length of anti–C. difficile